Methenamine / sodium salicylate Alternatives Compared
| Methenamine / sodium salicylate | Oxybutynin | VESIcare (solifenacin) |
|
|---|
| Methenamine / sodium salicylate | Oxybutynin | VESIcare (solifenacin) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Over-the-counter
Prescribed for Urinary Frequency. Methenamine / sodium salicylate may also be used for purposes not listed in this medication guide. |
Prescription and OTC
Oxybutynin helps to relieve symptoms of an overactive bladder and urinary incontinence but it may cause side effects such as a dry mouth and constipation. Prescribed for Overactive Bladder... View more |
Prescription only
Prescribed for Overactive Bladder, Urinary Frequency, Urinary Incontinence. VESIcare may also be used for purposes not listed in this medication guide. |
Related suggestions Urinary Frequency
|
|||||||||||||||||||||||
| More about Methenamine / sodium salicylate | More about Oxybutynin | More about VESIcare (solifenacin) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Methenamine / sodium salicylate has an average rating of 10.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Oxybutynin has an average rating of 6.7 out of 10 from a total of 461 ratings on Drugs.com. 54% of reviewers reported a positive effect, while 24% reported a negative effect. |
VESIcare has an average rating of 5.6 out of 10 from a total of 144 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 35% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Oxybutynin side effects |
View all VESIcare side effects |
|||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
|
View all Oxybutynin prices |
View all VESIcare prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Cystex Urinary Pain Relief, Uro-Pain Dual Action | Oxytrol, Oxytrol for Women | Other solifenacin brands include: VESIcare LS | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
2.3 hours |
68 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 311 drugs are known to interact with Methenamine / sodium salicylate:
|
A total of 287 drugs are known to interact with Oxybutynin:
|
A total of 498 drugs are known to interact with VESIcare:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
July 16, 1975 |
November 19, 2004 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.